Glucokinase Activation Strategies in Type 2 Diabetes Management

Glucokinase (GK) serves as a pivotal glucose sensor in hepatocytes and pancreatic β-cells, regulating the first committed step of glycolysis and orchestrating insulin secretion and hepatic glucose uptake. In type 2 diabetes, diminished GK activity contributes to impaired postprandial glycaemic control and β-cell dysfunction. Glucokinase activators (GKAs) have emerged as a therapeutic class designed to enhance GK catalytic efficiency or affinity for glucose, thus improving both insulin release and hepatic glucose clearance. Early-generation GKAs achieved robust short-term glucose lowering but suffered from hypoglycaemia risk, hypertriglyceridaemia and waning efficacy over time, often linked to disrupted interaction with the glucokinase regulatory protein (GKRP). Current research focuses on dual-acting molecules that target liver and pancreas with tissue selectivity, novel scaffolds derived from natural products, and strategies to preserve GK–GKRP dynamics to sustain long-term benefits while minimising lipid accumulation.

Research from Nature Portfolio

Recent clinical evaluation of dorzagliatin as add-on therapy to metformin demonstrated a mean reduction in HbA1c exceeding 1% over 24 weeks, with comparable adverse-event rates to placebo and no severe hypoglycaemia, underscoring its favourable tolerability profile. A phase I study of dorzagliatin co-administered with sitagliptin revealed no significant pharmacokinetic interactions and enhanced postprandial glycaemic responses, supporting combination regimens for dual pathway modulation. Seminal structure-based screening studies have also uncovered mangiferin as a natural-product GKA that activates GK at micromolar concentrations and improves glucose tolerance in diabetic models without precipitating hypoglycaemia, highlighting the utility of novel allosteric scaffolds.

Glucokinase Activation Strategies in Type 2 Diabetes Management publication trend

The graph below shows the total number of articles in glucokinase activation strategies in type 2 diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Glucokinase (GK): a hexokinase isoform that senses plasma glucose levels in hepatocytes and pancreatic β-cells by catalysing the phosphorylation of glucose to glucose-6-phosphate.

Glucokinase activator (GKA): a small molecule that increases GK catalytic rate or glucose affinity, employed to enhance insulin secretion and hepatic glucose uptake.

Glucokinase regulatory protein (GKRP): a liver-specific binding partner that sequesters GK in the nucleus at low glucose levels, controlling its cytoplasmic activity.

Pancreatic β-cell: an endocrine cell in the pancreatic islets that secretes insulin in response to glucose metabolism mediated by GK.

References

1. A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity. Nature Communications (2023).
2. Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study. Cardiovascular Diabetology (2024).
3. Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants. Biochemical Pharmacology (2024).
4. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. International Journal of Molecular Sciences (2024).
5. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine (2022).
6. An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism*. Journal of Biological Chemistry (2006).
7. Identification of mangiferin as a potential Glucokinase activator by structure-based virtual ligand screening. Scientific Reports (2017).